CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞重定向策略的出现,包括CAR-T 细胞和双特异性抗体,显著改善了复发/难治性大B细胞淋巴瘤患者的预后。当前正在进行的临床试验正在探索其在更早期治疗线中的作用,迅速重塑该疾病的治疗格局。该领域已从适合移植的概念转变为适合CAR-T 细胞的概念,尽管当前试验仍考虑前者来定义目标患者人群。在此,我们讨论2个临床病例,以有意说明T细胞重定向策略的这一动态时代,突出主要学习要点,同时也呈现未来需要解决的机会和未解问题。
The advent of T-cell redirecting strategies, including chimeric antigen receptor T cells and bispecific antibodies, has significantly improved the prognosis of patients with relapsed/refractory large B-cell lymphoma.
Current, ongoing clinical trials are exploring their role in earlier treatment lines, rapidly reshaping the treatment landscape of this disease entity. The field has shifted from the concept of transplant-eligible to chimeric antigen receptor T-cell eligible, albeit current trials still consider the former to define the target patient population.
Here, we discuss 2 clinical cases to deliberately illustrate this dynamic era of T-cell redirecting strategies, highlighting the main learning points but also presenting the opportunities and open questions to be addressed in the future.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。